Maj‐Britt Jensen

17.7k total citations · 6 hit papers
184 papers, 12.6k citations indexed

About

Maj‐Britt Jensen is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Maj‐Britt Jensen has authored 184 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Cancer Research, 115 papers in Oncology and 42 papers in Pathology and Forensic Medicine. Recurrent topics in Maj‐Britt Jensen's work include Breast Cancer Treatment Studies (110 papers), Breast Lesions and Carcinomas (41 papers) and HER2/EGFR in Cancer Research (39 papers). Maj‐Britt Jensen is often cited by papers focused on Breast Cancer Treatment Studies (110 papers), Breast Lesions and Carcinomas (41 papers) and HER2/EGFR in Cancer Research (39 papers). Maj‐Britt Jensen collaborates with scholars based in Denmark, United States and Sweden. Maj‐Britt Jensen's co-authors include Marianne Ewertz, Henning T. Mouridsen, Niels Kroman, Marie Overgaard, Carsten Rose, Jens Overgaard, Michael Kjær, Per Syrak Hansen, C. Gadeberg and Bent Ejlertsen and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Maj‐Britt Jensen

167 papers receiving 12.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

2013 2.7k citations Marianne Ewertz, Maj‐Britt Jensen et al. profile →
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy

1997 1.9k citations Jens Overgaard, Henning T. Mouridsen et al. profile →
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

1999 1.2k citations Maj‐Britt Jensen, Jens Overgaard et al. profile →
Prevalence of and Factors Associated With Persistent Pain Following Breast Cancer Surgery

2009 642 citations Maj‐Britt Jensen, Marianne Ewertz et al. profile →
RNA Polymerase IV Directs Silencing of Endogenous DNA

2005 535 citations Alan J. Herr, Maj‐Britt Jensen et al. Science profile →
Sunscreens: are they beneficial for health? An overview of endocrine disrupting properties of UV‐filters

2012 353 citations Maj‐Britt Jensen et al. profile →

Peers

Countries citing papers authored by Maj‐Britt Jensen

Since Specialization

Citations

This map shows the geographic impact of Maj‐Britt Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maj‐Britt Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maj‐Britt Jensen more than expected).

Fields of papers citing papers by Maj‐Britt Jensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maj‐Britt Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maj‐Britt Jensen. The network helps show where Maj‐Britt Jensen may publish in the future.

Co-authorship network of co-authors of Maj‐Britt Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Maj‐Britt Jensen. A scholar is included among the top collaborators of Maj‐Britt Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maj‐Britt Jensen. Maj‐Britt Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer 2025 ·Neoplasia ·Tobias Berg, Lise Barlebo Ahlborn, Maj‐Britt Jensen, Ann Knoop, Bent Ejlertsen, Maria Rossing	0
2	Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo 2025 ·Clinical Epidemiology ·Signe Borgquist, Maj‐Britt Jensen, (unknown), Peer Christiansen, Birgitte Vrou Offersen, Annette Raskov Kodahl, Marianne Ewertz, Anders Bonde Jensen, Thomas P. Ahern, Deirdre Cronin‐Fenton, Bent Ejlertsen	4
3	Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1 2025 ·Radiotherapy and Oncology ·Mette S. Thomsen, Ebbe Laugaard Lorenzen, Jan Alsner, (unknown), Esben Svitzer Yates, Martin Berg, (unknown), (unknown), Carine Kirkove, I. Jensen, (unknown), (unknown), (unknown), (unknown), Melanie Hasler, Knud Andersen, (unknown), Maj‐Britt Jensen, Birgitte Vrou Offersen	0
4	Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000 2025 ·Acta Oncologica ·(unknown), Maj‐Britt Jensen, Bent Ejlertsen, Mads Thomassen, Maria Rossing, Inge Søkilde Pedersen, Annabeth Høgh Petersen, Lise Lotte Christensen, Karin Wadt, Anne‐Vibeke Lænkholm	1
5	Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost 2024 ·Radiotherapy and Oncology ·Mette S. Thomsen, Jan Alsner, Christina Maria Lutz, Martin Berg, Ingelise Jensen, Ebbe Laugaard Lorenzen, Hanne Melgaard Nielsen, Erik Jakobsen, Lars Stenbygaard, Mette Holck Nielsen, Maj‐Britt Jensen, Jens Overgaard, Birgitte Vrou Offersen	2
6	Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer 2024 ·JAMA Network Open ·Tobias Berg, Maj‐Britt Jensen, Maria Rossing, Troels Bechmann, Frede Donskov, Ann Knoop, Bent Ejlertsen	4
7	Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer 2024 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Stig E. Bojesen, Julia S. Johansen, Bent Ejlertsen, Tobias Berg, Malgorzata Tuxen, Kasper Madsen, Hella Danø, Henrik Flyger, Maj‐Britt Jensen, Dorte Nielsen	1
8	Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world patients. 2023 ·PubMed ·(unknown), Ann Knoop, Maj‐Britt Jensen, Tobias Berg, Hanne Melgaard Nielsen, Iben Kümler	0
9	Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study 2023 ·npj Breast Cancer ·Maj‐Britt Jensen, Christina B. Pedersen, (unknown), (unknown), L.J. Gibson, (unknown), (unknown), Ilse Vejborg, Niels Kroman, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing	4
10	Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study 2022 ·JNCI Journal of the National Cancer Institute ·Søren Cold, Frederik Cold, Maj‐Britt Jensen, Deirdre Cronin‐Fenton, Peer Christiansen, Bent Ejlertsen	57
11	Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial 2022 ·Journal of Clinical Oncology ·Birgitte Vrou Offersen, Jan Alsner, Hanne Melgaard Nielsen, Erik Jakobsen, Mette Holck Nielsen, Lars Stenbygaard, Anders N. Pedersen, Mette S. Thomsen, Esben Svitzer Yates, Martin Berg, Ebbe Laugaard Lorenzen, Ingelise Jensen, Mirjana Josipović, Maj‐Britt Jensen, Jens Overgaard	44
12	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial 2022 ·Cancers ·(unknown), Elisabeth Specht Stovgaard, Maj‐Britt Jensen, Karama Asleh, Nazia Riaz, Dongxia Gao, Samuel Leung, Bent Ejlertsen, Anne‐Vibeke Lænkholm, Torsten O. Nielsen	2
13	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer 2021 ·British Journal of Cancer ·(unknown), Thomas Vauvert F. Hviid, (unknown), (unknown), Jens Ole Eriksen, Bent Ejlertsen, Anne‐Marie Gerdes, Torben A. Kruse, Mads Thomassen, Maj‐Britt Jensen, Anne‐Vibeke Lænkholm	11
14	Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women 2021 ·Clinical Cancer Research ·Lindsay J. Collin, Deirdre Cronin‐Fenton, Thomas P. Ahern, Michael Goodman, Lauren E. McCullough, Lance A. Waller, Anders Kjærsgaard, Per Damkier, Peer Christiansen, Bent Ejlertsen, Maj‐Britt Jensen, Henrik Toft Sørensen, Timothy L. Lash	33
15	Survival in Women Diagnosed With Breast Cancer During Pregnancy 2021 ·Clinical Breast Cancer ·(unknown), (unknown), Mona Aarenstrup Karlsen, Lone Storgaard, Niels Kroman, Maj‐Britt Jensen, (unknown), Cristel Sørensen Hjortshøj, Bent Ejlertsen, Jeanette Falck Winther, Susanne K. Kjær, Lene Mellemkjær	5
16	Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study 2020 ·British journal of surgery ·(unknown), Maj‐Britt Jensen, Lisbet Rosenkrantz Hölmich, Anne Bodilsen, Rob A.�E.�M. Tollenaar, Anne‐Vibeke Lænkholm, Birgitte Vrou Offersen, Bent Ejlertsen, Marc A.M. Mureau, Peer Christiansen	27
17	Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG) 2020 ·The Breast ·Tobias Berg, Maj‐Britt Jensen, Erik Jakobsen, (unknown), (unknown), Michael Andersson	13
18	RNA Polymerase IV Directs Silencing of Endogenous DNA breakdown → 2005 ·Science ·Alan J. Herr, Maj‐Britt Jensen, Tamás Dalmay, David C. Baulcombe	535
19	[Mammography screening in the county of Copenhagen. Results of the first three screening rounds]. 2002 ·PubMed ·Ulla Brix Tange, Fred R. Hirsch, Maj‐Britt Jensen, Anne Helene Olsen, M Blichert-Toft, Fritz Rank, Ilse Vejborg, Henning T. Mouridsen, Elsebeth Lynge	6
20	[Mammographic screening in the county of Copenhagen. Clinical consequences of the first three screening rounds]. 2002 ·PubMed ·Ulla Brix Tange, Fred R. Hirsch, Maj‐Britt Jensen, Anne Helene Olsen, M Blichert-Toft, Fritz Rank, Ilse Vejborg, Henning T. Mouridsen, Elsebeth Lynge	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact